Abstract
Background: Three new series of coumarin derivatives 4a-e, 6a-d and 7a-d were synthesized and characterized by elemental analyses and spectral data including 2D NMR. All compounds 4a-e, 6a-d and 7a-d were evaluated for their in vitro antioxidant and anticancer activity against Hep-G2 hepatic cancer and MCF-7 breast cancer cell lines.
Method: Compounds 4c, 4e, 6d and 7c showed higher antioxidant activity (IC50 = 78, 20, 90 and 46 μM, respectively) than the reference drug silymarin (IC50 = 76 μM). Results and Conclusion: However, the anticancer screening for the three series showed promising anticancer activity against hepatic Hep-G2 cancer cell line and compounds 4d, 4e, 6a and 6c (IC50 = 1890, 5327, 5715 and 10339 μM, respectively) have more potent cytotoxic activity than cisplatin (IC50 = 11898 μM). On the other hand, all compounds showed no anticancer activity against MCF-7 cell line except compound 6a with IC50 = 32441 μM in comparison with cisplatin (IC50 = 15030 μM).Keywords: Coumarin, pyrazole, isoxazole, thiazole, antioxidant, anticancer.
Letters in Drug Design & Discovery
Title:Design, Synthesis, Antioxidant and Anticancer Activity of New Coumarin Derivatives Linked with Thiazole, Isoxazole or Pyrazole Moiety
Volume: 14 Issue: 7
Author(s): Khaled R. A. Abdellatif*, Mohamed A. Abdelgawad, Heba A. H. Elshemy, Nesma M. Kahk and Dalia M. El Amir
Affiliation:
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni- Suef,Egypt
Keywords: Coumarin, pyrazole, isoxazole, thiazole, antioxidant, anticancer.
Abstract: Background: Three new series of coumarin derivatives 4a-e, 6a-d and 7a-d were synthesized and characterized by elemental analyses and spectral data including 2D NMR. All compounds 4a-e, 6a-d and 7a-d were evaluated for their in vitro antioxidant and anticancer activity against Hep-G2 hepatic cancer and MCF-7 breast cancer cell lines.
Method: Compounds 4c, 4e, 6d and 7c showed higher antioxidant activity (IC50 = 78, 20, 90 and 46 μM, respectively) than the reference drug silymarin (IC50 = 76 μM). Results and Conclusion: However, the anticancer screening for the three series showed promising anticancer activity against hepatic Hep-G2 cancer cell line and compounds 4d, 4e, 6a and 6c (IC50 = 1890, 5327, 5715 and 10339 μM, respectively) have more potent cytotoxic activity than cisplatin (IC50 = 11898 μM). On the other hand, all compounds showed no anticancer activity against MCF-7 cell line except compound 6a with IC50 = 32441 μM in comparison with cisplatin (IC50 = 15030 μM).Export Options
About this article
Cite this article as:
Abdellatif R. A. Khaled*, Abdelgawad A. Mohamed, Elshemy A. H. Heba, Kahk M. Nesma and El Amir M. Dalia, Design, Synthesis, Antioxidant and Anticancer Activity of New Coumarin Derivatives Linked with Thiazole, Isoxazole or Pyrazole Moiety, Letters in Drug Design & Discovery 2017; 14 (7) . https://dx.doi.org/10.2174/1570180813666161026153743
DOI https://dx.doi.org/10.2174/1570180813666161026153743 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology Epigenetic Regulation of EMT: The Snail Story
Current Pharmaceutical Design Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design The Role of MicroRNAs in Diagnosis, Prognosis, Metastasis and Resistant Cases in Breast Cancer
Current Pharmaceutical Design Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Current Drug Targets Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis
Current Pharmaceutical Design When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
Current Cancer Drug Targets Molecular Hybrids of N-Phthaloylglycyl Hydrazide and Hydrazinecarbothioamide with Anti-inflammatory and Anti-oxidant Activities
Current Organic Synthesis Optimized Methods for In Vitro and In Vivo Anti-Inflammatory Assays and Its Applications in Herbal and Synthetic Drug Analysis
Mini-Reviews in Medicinal Chemistry Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Syntheses of the Ammonium Salts of 7-Carbamate Derivatives of Quercetin
Letters in Organic Chemistry Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities
Mini-Reviews in Medicinal Chemistry Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Helenalin - A Sesquiterpene Lactone with Multidirectional Activity
Current Drug Targets Pathogenesis and Biomarkers in Spondyloarthritis: Clues from Microarray Analyses
Current Rheumatology Reviews